Xingying He

Dr. Xingying He

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2013 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
PDF file
HZHao Zhang
Hao Zhang
SZShao‐Bo Zhang
Shao‐Bo Zhang
QZQing‐Qing Zhang
Qing‐Qing Zhang
MLMeng Liu
Meng Liu
XHXingying He
Xingying He
XSXue‐Yin Shi
Xue‐Yin Shi
Aims The intravenous anesthetic propofol caused episodic memory impairments in human. We hypothesized propofol caused episodic‐like spatial memory retention but not acquisition impairments in rats and rescuing cAMP response element‐binding protein (CREB) signaling using selective type IV phosphodiesterase (PDEIV) inhibitor rolipram reversed these effects. Methods Male Sprague‐Dawley rats were randomized into four groups: control; propofol (25 mg/kg, intraperitoneal); rolipram; and rolipram + propofol (pretreatment of rolipram 25 min before propofol, 0.3 mg/kg, intraperitoneal). Sedation and motor coordination were evaluated 5, 15, and 25 min after propofol injection. Invisible Morris water maze (MWM) acquisition and probe test (memory retention) were performed 5 min and 24 h after propofol injection. Visible MWM training was simultaneously performed to resist nonspatial effects. Hippocampal CREB signaling was detected 5 min, 50 min, and 24 h after propofol administration. Results Rolipram did not change propofol‐induced anesthetic/sedative states or impair motor skills. No difference was found on the latency to the platform during the visible MWM. Propofol impaired spatial memory retention but not acquisition. Rolipram reversed propofol‐induced spatial memory impairments and suppression on cAMP levels, CaMKIIα and CREB phosphorylation, brain‐derived neurotropic factor (BDNF) and Arc protein expression. Conclusions Propofol caused spatial memory retention impairments but not acquisition inability possibly by inhibiting CREB signaling.

22 May 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
SDShiyun Dai
Shiyun Dai
JJJun Ji
Jun Ji
RLRongrong Li
Rongrong Li
LGLu Gao
Lu Gao
XHXingying He
Xingying He
Stellate ganglion blocks (SGBs) has been applied in clinics to alleviate pain-related syndromes for almost a century. In recent years, it has been reported that SGB can attenuate acute lung injury (ALI) in animals. However, the details of these molecular mechanisms remain complex and unclear. In this study, rats were randomly divided into four groups: group C (receiving no treatment), group NS (receiving the intratracheal instillation of normal saline), group L (receiving the intratracheal instillation of LPS) and group LS (receiving SGB after the intratracheal instillation of LPS). The pathological damage of lung tissue, arterial blood gases, the differentiation of alveolar macrophages (AMs) and inflammatory cytokines (IL-1β, IL-6, IL-10) were detected. Furthermore, the oxidative stress indexes (ROS, CYP-D, T-SOD, Mn-SOD and CAT) in serum and the levels of Sirt3 signaling-associated proteins (JAK2/STAT3, NF-κb p65, CIRP and NLRP3) in the lungs were measured. The results revealed that SGB could attenuate lung tissue damage, improve pulmonary oxygenation, promote the differentiation of AMs to the M2 phenotype, decrease the secretion of IL-1β and IL-6, and increase the secretion of IL-10. Meanwhile, SGB was found to inhibit the production of ROS and CYP-D, and enhance the activities of T-SOD, Mn-SOD and CAT. Furthermore, SGB upregulated Sirt3 and downregulated JAK2/STAT3 and NF-κb p65 phosphorylation, CIRP and NLRP3. Our work revealed that SGB could attenuate LPS-induced ALI by activating the Sirt3-mediated regulation of oxidative stress and pulmonary inflammation; this may shed new light upon the protection of SGB and provide a novel prophylactic strategy for LPS-induced ALI.

17 November 2025 in BMC Anesthesiology
Verified
Journal Article
Open access
PDF file
RLRongrong Li
Rongrong Li
HYHao Yin
Hao Yin
WLWeijun Luo
Weijun Luo
YYYutong Yang
Yutong Yang
HYHongbin Yuan
Hongbin Yuan
XHXingying He
Xingying He
Background: Laparoscopic cholecystectomy (LC) is a widely adopted minimally invasive procedure for the treatment of gallbladder diseases. However, postoperative pain remains a significant clinical challenge, with more than 30% of patients experiencing moderate to severe pain, which may prolong hospital stays and impede enhanced recovery after surgery (ERAS) protocols. Hydromorphone, a potent semisynthetic opioid with rapid onset and prolonged analgesic effects, has been employed for preemptive analgesia in LC. This agent has greater analgesic potency and a potentially more favourable side effect profile than morphine does. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of hydromorphone as a preemptive analgesic in patients undergoing LC. Methods: A comprehensive literature search was conducted across multiple databases, including PubMed, Cochrane, Embase, Web of Science, CNKI, VIP, Wanfang Data, and CBM, from their inception to 2025. Studies assessing the efficacy and safety of hydromorphone for pre-emptive analgesia in LC recipients were included. Additional relevant publications were identified by reviewing references from retrieved articles and searching for commercial system names. Meta-analyses were performed using fixed- or random-effects models on the basis of heterogeneity levels. Results: Seventeen studies involving a total of 1,515 patients (hydromorphone group, n = 761; control group, n = 754) were included. The control group received either normal saline or no treatment. Compared with controls, patients treated with hydromorphone presented significantly decreased pain intensity at multiple postoperative time points ( P < 0.05); shortened extubation time ( P < 0.05); a reduced incidence of emergence agitation ( P < 0.05); and improved haemodynamic stability, as evidenced by reduced numbers of fluctuations in heart rate and mean arterial pressure ( P < 0.05). Additionally, hydromorphone was associated with decreased levels of inflammatory markers (IL-1, IL-8, and TNF-α; P < 0.05). No significant difference was observed in the incidence of postoperative nausea and vomiting (PONV) between the two groups. Conclusion: The outcomes of this study substantiate the efficacy and safety of hydromorphone in the management of postoperative pain, demonstrating superiority over placebo or no treatment.

1 June 2026 in Molecular Medicine
Verified
Journal Article
Open access
XMXiaoyan Meng
Xiaoyan Meng
HWHuawei Wei
Huawei Wei
JCJiao Cai
Jiao Cai
YHYiman Han
Yiman Han
HWHaowei Wang
Haowei Wang
HYHongbin Yuan
Hongbin Yuan
Sepsis survivors who develop recurrent or secondary infections often exhibit prolonged immunosuppression and impaired pathogen clearance, yet the underlying mechanisms remain poorly defined and targeted therapies are limited. We established a murine second-hit sepsis model to examine immune remodeling during the immunosuppressive phase after an initial inflammatory insult. Bone marrow immune remodeling was characterized by flow cytometry and single-cell RNA sequencing. Purified myeloid subsets were subjected to functional assays, transcriptomic analyses, and molecular studies to define how Slfn4 regulates the suppressive program of monocytic myeloid-derived suppressor cell-like (M-MDSC-like) cells. We found that Slfn4 marks an immunosuppressive M-MDSC-like subset in the bone marrow during second-hit sepsis, and our data support a role for the Slfn4-Stat3 axis in maintaining its suppressive phenotype. Genetic silencing of Slfn4 or pharmacologic inhibition of Stat3 was associated with reduced M-MDSC-like cell abundance, partially restored T-cell function, and improved survival. Mechanistically, our data supports a model in which SLFN4 enhances Stat3 activation in association with post-transcriptional repression of Socs3, potentially through interaction with an AU-rich element within the Socs3 3'-UTR. In addition, sildenafil, a PDE5 inhibitor, decreased M-MDSC-like cell abundance and enhanced bacterial clearance in vivo. These findings implicate the Slfn4-Stat3 axis in bone marrow-associated immunosuppression in this murine second-hit sepsis model and support further investigation of this pathway in the late immunosuppressive phase of sepsis.